Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,97.3,14290,DB00852,Pseudoephedrine
,15303659,recovery,"The within-day and between-day RSD were less than 12.4%, and the average recovery was between 97.3% - 109.4%.",[Simultaneous determination of pseudoephedrine and chlorpheniramine in human plasma by HPLC-UV detection method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15303659/),%,109.4,14291,DB00852,Pseudoephedrine
,32133778,Maximum plasma concentration,"Maximum plasma concentration of triprolidine for the 2.5 mg and dose-normalized 5 mg single-agent tablets were comparable (8.4 versus 7.1 ng/mL, respectively) and higher for the combination tablet (9.5 ng/mL).","Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133778/),[ng] / [ml],8.4,16697,DB00852,Pseudoephedrine
,32133778,Maximum plasma concentration,"Maximum plasma concentration of triprolidine for the 2.5 mg and dose-normalized 5 mg single-agent tablets were comparable (8.4 versus 7.1 ng/mL, respectively) and higher for the combination tablet (9.5 ng/mL).","Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133778/),[ng] / [ml],7.1,16698,DB00852,Pseudoephedrine
,32133778,Maximum plasma concentration,"Maximum plasma concentration of triprolidine for the 2.5 mg and dose-normalized 5 mg single-agent tablets were comparable (8.4 versus 7.1 ng/mL, respectively) and higher for the combination tablet (9.5 ng/mL).","Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133778/),[ng] / [ml],9.5,16699,DB00852,Pseudoephedrine
,32133778,time to maximum plasma concentration,"PK parameters, including time to maximum plasma concentration (∼1.5 hours) and elimination half-life (∼4 hours), were comparable between the 3 treatment arms.","Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32133778/),h,∼1.5,16700,DB00852,Pseudoephedrine
,25427591,detection limit,It was found that the CL intensity of luminol-Pep reaction could be remarkably inhibited by pseudoephedrine (PE); the decrement of CL intensity was linear to the logarithm of PE concentration in the range of 0.1∼100.0 nmol L(-1) with a detection limit of 0.03 nmol mL(-1) (3σ).,Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),[nM] / [ml],0.03,20892,DB00852,Pseudoephedrine
,25427591,flow rate,"At a flow rate of 2.0 mL min(-1), the complete process including washing and sampling was performed within 40 s, offering a sample throughput of 90 h(-1).",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),[ml] / [min],2.0,20893,DB00852,Pseudoephedrine
,25427591,sample throughput,"At a flow rate of 2.0 mL min(-1), the complete process including washing and sampling was performed within 40 s, offering a sample throughput of 90 h(-1).",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),1/[h],90,20894,DB00852,Pseudoephedrine
,25427591,elimination ratio,This proposed method was successfully applied to determining PE in rat serum for 18 h after intragastric administration with the elimination ratio of 42.34 % and recoveries from 90.3 to 110.6 %.,Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),%,42.34,20895,DB00852,Pseudoephedrine
,25427591,recoveries,This proposed method was successfully applied to determining PE in rat serum for 18 h after intragastric administration with the elimination ratio of 42.34 % and recoveries from 90.3 to 110.6 %.,Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),%,90.3 to 110.6,20896,DB00852,Pseudoephedrine
,25427591,peak concentration (C max),"The pharmacokinetic results showed that PE could be rapidly absorbed into serum with peak concentration (C max) of 1.45 ± 0.18 g L(-1) at the time (T max) of 1.49 ± 0.02 h; the absorption half-life (0.35 ± 0.04 h), elimination half-life (1.86 ± 0.24 h), the area under curve (109.81 ± 6.03 mg L(-1) h(-1)), mean residence time (3.82 ± 0.27 h), and elimination rate constant (2.26 ± 0.23 L g(-1) h(-1)) in rats vivo were derived, respectively.",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),[g] / [l],1.45,20897,DB00852,Pseudoephedrine
,25427591,time (T max),"The pharmacokinetic results showed that PE could be rapidly absorbed into serum with peak concentration (C max) of 1.45 ± 0.18 g L(-1) at the time (T max) of 1.49 ± 0.02 h; the absorption half-life (0.35 ± 0.04 h), elimination half-life (1.86 ± 0.24 h), the area under curve (109.81 ± 6.03 mg L(-1) h(-1)), mean residence time (3.82 ± 0.27 h), and elimination rate constant (2.26 ± 0.23 L g(-1) h(-1)) in rats vivo were derived, respectively.",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),h,1.49,20898,DB00852,Pseudoephedrine
,25427591,absorption half-life,"The pharmacokinetic results showed that PE could be rapidly absorbed into serum with peak concentration (C max) of 1.45 ± 0.18 g L(-1) at the time (T max) of 1.49 ± 0.02 h; the absorption half-life (0.35 ± 0.04 h), elimination half-life (1.86 ± 0.24 h), the area under curve (109.81 ± 6.03 mg L(-1) h(-1)), mean residence time (3.82 ± 0.27 h), and elimination rate constant (2.26 ± 0.23 L g(-1) h(-1)) in rats vivo were derived, respectively.",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),h,0.35,20899,DB00852,Pseudoephedrine
,25427591,elimination half-life,"The pharmacokinetic results showed that PE could be rapidly absorbed into serum with peak concentration (C max) of 1.45 ± 0.18 g L(-1) at the time (T max) of 1.49 ± 0.02 h; the absorption half-life (0.35 ± 0.04 h), elimination half-life (1.86 ± 0.24 h), the area under curve (109.81 ± 6.03 mg L(-1) h(-1)), mean residence time (3.82 ± 0.27 h), and elimination rate constant (2.26 ± 0.23 L g(-1) h(-1)) in rats vivo were derived, respectively.",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),h,1.86,20900,DB00852,Pseudoephedrine
,25427591,area under curve,"The pharmacokinetic results showed that PE could be rapidly absorbed into serum with peak concentration (C max) of 1.45 ± 0.18 g L(-1) at the time (T max) of 1.49 ± 0.02 h; the absorption half-life (0.35 ± 0.04 h), elimination half-life (1.86 ± 0.24 h), the area under curve (109.81 ± 6.03 mg L(-1) h(-1)), mean residence time (3.82 ± 0.27 h), and elimination rate constant (2.26 ± 0.23 L g(-1) h(-1)) in rats vivo were derived, respectively.",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),[mg] / [h·l],109.81,20901,DB00852,Pseudoephedrine
,25427591,mean residence time,"The pharmacokinetic results showed that PE could be rapidly absorbed into serum with peak concentration (C max) of 1.45 ± 0.18 g L(-1) at the time (T max) of 1.49 ± 0.02 h; the absorption half-life (0.35 ± 0.04 h), elimination half-life (1.86 ± 0.24 h), the area under curve (109.81 ± 6.03 mg L(-1) h(-1)), mean residence time (3.82 ± 0.27 h), and elimination rate constant (2.26 ± 0.23 L g(-1) h(-1)) in rats vivo were derived, respectively.",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),h,3.82,20902,DB00852,Pseudoephedrine
,25427591,elimination rate constant,"The pharmacokinetic results showed that PE could be rapidly absorbed into serum with peak concentration (C max) of 1.45 ± 0.18 g L(-1) at the time (T max) of 1.49 ± 0.02 h; the absorption half-life (0.35 ± 0.04 h), elimination half-life (1.86 ± 0.24 h), the area under curve (109.81 ± 6.03 mg L(-1) h(-1)), mean residence time (3.82 ± 0.27 h), and elimination rate constant (2.26 ± 0.23 L g(-1) h(-1)) in rats vivo were derived, respectively.",Pharmacokinetic of pseudoephedrine in rat serum with luminol-pepsin chemiluminescence system by flow injection analysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427591/),[l] / [g·h],2.26,20903,DB00852,Pseudoephedrine
,17452029,flow rate,"Reverse-phase HPLC separation was accomplished on a Zorbax SB-C18 column (100 mm x 3.0 mm, 3.5 microm) with a mobile phase composed of methanol-water-formic acid (65:35:0.5, v/v/v) at a flow rate of 0.2 mL/min.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),[ml] / [min],0.2,43873,DB00852,Pseudoephedrine
,17452029,total run time,The method had a chromatographic total run time of 5 min.,Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),min,5,43874,DB00852,Pseudoephedrine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,136.0,43875,DB00852,Pseudoephedrine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,91.0,43876,DB00852,Pseudoephedrine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,256.0,43877,DB00852,Pseudoephedrine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,166.1,43878,DB00852,Pseudoephedrine
,8917241,terminal elimination half-life,"In children, the mean (+/-SEM) terminal elimination half-life values for pseudoephedrine, 3.1 +/- 0.5 hours, and for phenylpropanolamine, 2.6 +/- 0.6 hours, were significantly shorter than those found by other investigators in adults.",Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917241/),h,3.1,52266,DB00852,Pseudoephedrine
,8917241,terminal elimination half-life,"In children, the mean (+/-SEM) terminal elimination half-life values for pseudoephedrine, 3.1 +/- 0.5 hours, and for phenylpropanolamine, 2.6 +/- 0.6 hours, were significantly shorter than those found by other investigators in adults.",Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917241/),h,2.6,52267,DB00852,Pseudoephedrine
,7507589,bioavailability,"Both PPA and PDE are readily and completely absorbed, whereas PE, with a bioavailability of only approximately 38%, is subject to gut wall metabolism and is thought to be absorbed erratically.",Pharmacokinetics of oral decongestants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),%,38,59010,DB00852,Pseudoephedrine
,7507589,apparent volume of distribution,All three drugs are extensively distributed into extravascular sites (apparent volume of distribution between 2.6 and 5.0 L/kg).,Pharmacokinetics of oral decongestants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),[l] / [kg],2.6 and 5.0,59011,DB00852,Pseudoephedrine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,2.5,59012,DB00852,Pseudoephedrine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,4,59013,DB00852,Pseudoephedrine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,6,59014,DB00852,Pseudoephedrine
,19021932,peak concentration,"However, the highest amount of ephedrines in urine was ephedrine and the peak concentration was 4.35 +/- 1.82 microg/mL (mean +/- standard deviation), which was lower than the WADA permitted value (10 microg/mL).",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),[μg] / [ml],4.35,61476,DB00852,Pseudoephedrine
,19021932,peak concentration,"However, the highest amount of ephedrines in urine was ephedrine and the peak concentration was 4.35 +/- 1.82 microg/mL (mean +/- standard deviation), which was lower than the WADA permitted value (10 microg/mL).",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),,10,61477,DB00852,Pseudoephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,5.2,61478,DB00852,Pseudoephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,4.2,61479,DB00852,Pseudoephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,4.2,61480,DB00852,Pseudoephedrine
,19021932,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were: 5.2 +/- 1.2, 4.2 +/- 1.3, 4.2 +/- 0.9, and 6.5 +/- 2.8 h, respectively.",Urinary elimination of ephedrines following administration of the Traditional Chinese Medicine preparation Kakkon-to. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021932/),h,6.5,61481,DB00852,Pseudoephedrine
,14531724,elimination half-life,"The elimination half-life of linezolid is 5-7 hours, and twice-daily administration of 400-600 mg provides steady-state concentrations in the therapeutic range.","Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531724/),h,5-7,79676,DB00852,Pseudoephedrine
,22936420,flow rate,"Plasma samples were processed and analyzed on a Phenomenex Luna 3 μ CN 100A column (150 mm×2.0 mm) eluted with the mobile phase consisting of methanol and 0.01 mol/L ammonium acetate water solution containing 0.1% formic acid (45:55, v/v) at a flow rate of 0.2 mL/min.",Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),[ml] / [min],0.2,82874,DB00852,Pseudoephedrine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,91.82,82875,DB00852,Pseudoephedrine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,98.46,82876,DB00852,Pseudoephedrine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,90.77,82877,DB00852,Pseudoephedrine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,92.05,82878,DB00852,Pseudoephedrine
,29899212,time to maximum plasma concentration,"Median time to maximum plasma concentration for tedizolid and pseudoephedrine ranged from 3 to 4 h, regardless of treatment coadministration.",Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29899212/),h,3 to 4,93800,DB00852,Pseudoephedrine
,20446910,total body clearance (CL),"The total body clearance (CL) was the highest in rats (78 mL/min/kg), lowest in monkeys (15 mL/min/kg) and the dog averaged in between (33 mL/min/kg).","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),[ml] / [kg·min],78,94314,DB00852,Pseudoephedrine
,20446910,total body clearance (CL),"The total body clearance (CL) was the highest in rats (78 mL/min/kg), lowest in monkeys (15 mL/min/kg) and the dog averaged in between (33 mL/min/kg).","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),[ml] / [kg·min],15,94315,DB00852,Pseudoephedrine
,20446910,total body clearance (CL),"The total body clearance (CL) was the highest in rats (78 mL/min/kg), lowest in monkeys (15 mL/min/kg) and the dog averaged in between (33 mL/min/kg).","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),[ml] / [kg·min],33,94316,DB00852,Pseudoephedrine
,20446910,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) ranged from 3-5 L/kg in all species.,"Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),[l] / [kg],3-5,94317,DB00852,Pseudoephedrine
,20446910,half-lives (t1/2),"In rats and dogs, the mean half-lives (t1/2) was ≈1.5 hr, while in monkeys the mean t1/2 was 4.6 hr, comparable to that observed in adult humans (4-8 hr).","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),h,1.5,94318,DB00852,Pseudoephedrine
,20446910,t1/2,"In rats and dogs, the mean half-lives (t1/2) was ≈1.5 hr, while in monkeys the mean t1/2 was 4.6 hr, comparable to that observed in adult humans (4-8 hr).","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),h,4.6,94319,DB00852,Pseudoephedrine
,20446910,t1/2,"In rats and dogs, the mean half-lives (t1/2) was ≈1.5 hr, while in monkeys the mean t1/2 was 4.6 hr, comparable to that observed in adult humans (4-8 hr).","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),h,4-8,94320,DB00852,Pseudoephedrine
,20446910,oral bioavailability,"The oral bioavailability was 38, 58 and 78% in rats, dogs and monkeys.","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),%,38,94321,DB00852,Pseudoephedrine
,20446910,oral bioavailability,"The oral bioavailability was 38, 58 and 78% in rats, dogs and monkeys.","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),%,58,94322,DB00852,Pseudoephedrine
,20446910,oral bioavailability,"The oral bioavailability was 38, 58 and 78% in rats, dogs and monkeys.","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),%,78,94323,DB00852,Pseudoephedrine
,20446910,bioavailability,"The bioavailability following intra-ileum or intra-colonic administration in rats was superior to that following oral dosing (66% and 78%, respectively) suggesting that colonic absorption may be compensating for the short half-life, thus enabling successful QD sustained release formulations of PSE.","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),%,66,94324,DB00852,Pseudoephedrine
,20446910,bioavailability,"The bioavailability following intra-ileum or intra-colonic administration in rats was superior to that following oral dosing (66% and 78%, respectively) suggesting that colonic absorption may be compensating for the short half-life, thus enabling successful QD sustained release formulations of PSE.","Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),%,78,94325,DB00852,Pseudoephedrine
,20446910,EC50,The PK/PD in the cat model followed a sigmoid Emax model with an EC50 (plasma concentration that elicits 50% of the maximum response) of 0.32 ±0.05 (SD) µM consistent with human plasma concentrations required for efficacy.,"Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20446910/),μM,0.32,94326,DB00852,Pseudoephedrine
,18479880,total run time,The total run time was 12 min between injections.,"Pharmacokinetic study of matrine, oxymatrine and oxysophocarpine in rat plasma after oral administration of Sophora flavescens Ait. extract by liquid chromatography tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479880/),min,12,94642,DB00852,Pseudoephedrine
,15561855,clinical cure,"Overall, clinical cure and bacterial eradication rates were 91 and 90%, respectively, for S. pneumoniae and 93 and 92%, respectively, for the grouping of H. influenzae, H. parainfluenzae, and M. catarrhalis.",Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561855/),,91,95640,DB00852,Pseudoephedrine
,15561855,clinical cure,"Overall, clinical cure and bacterial eradication rates were 91 and 90%, respectively, for S. pneumoniae and 93 and 92%, respectively, for the grouping of H. influenzae, H. parainfluenzae, and M. catarrhalis.",Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561855/),,90,95641,DB00852,Pseudoephedrine
,15561855,clinical cure,"Overall, clinical cure and bacterial eradication rates were 91 and 90%, respectively, for S. pneumoniae and 93 and 92%, respectively, for the grouping of H. influenzae, H. parainfluenzae, and M. catarrhalis.",Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561855/),%,93,95642,DB00852,Pseudoephedrine
>,15561855,AUC(0-24)/MIC ratios,"The fu AUC(0-24)/MIC ratios were high (>90% were >200), and none of the pharmacokinetic-pharmacodynamic exposure measurements indexed to the MIC or other factors were significant predictors of clinical or bacteriologic response.",Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561855/),,200,95643,DB00852,Pseudoephedrine
,17939152,AUC(0-24),"After a single 0.2 mg dose for the test and reference product, the resulting means of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), C(max), T(max) and t(1/2) of huperzine A were 16.35 +/- 3.42 vs 16.38 +/- 3.61 ng h/mL, 17.53 +/- 3.80 vs 17.70 +/- 3.97 ng h/mL, 2.47 +/- 0.49 vs 2.51 +/- 0.51 ng/mL, 1.3 +/- 0.4 vs 1.2 +/- 0.3 h and 5.92 +/- 0.75 vs 6.18 +/- 0.66 h, respectively, indicating that these two kinds of tablets were bioequivalent.",Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17939152/),[h·ng] / [ml],16.35,97332,DB00852,Pseudoephedrine
,17939152,AUC(0-infinity),"After a single 0.2 mg dose for the test and reference product, the resulting means of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), C(max), T(max) and t(1/2) of huperzine A were 16.35 +/- 3.42 vs 16.38 +/- 3.61 ng h/mL, 17.53 +/- 3.80 vs 17.70 +/- 3.97 ng h/mL, 2.47 +/- 0.49 vs 2.51 +/- 0.51 ng/mL, 1.3 +/- 0.4 vs 1.2 +/- 0.3 h and 5.92 +/- 0.75 vs 6.18 +/- 0.66 h, respectively, indicating that these two kinds of tablets were bioequivalent.",Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17939152/),[h·ng] / [ml],16.38,97333,DB00852,Pseudoephedrine
,17939152,t(1/2),"After a single 0.2 mg dose for the test and reference product, the resulting means of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), C(max), T(max) and t(1/2) of huperzine A were 16.35 +/- 3.42 vs 16.38 +/- 3.61 ng h/mL, 17.53 +/- 3.80 vs 17.70 +/- 3.97 ng h/mL, 2.47 +/- 0.49 vs 2.51 +/- 0.51 ng/mL, 1.3 +/- 0.4 vs 1.2 +/- 0.3 h and 5.92 +/- 0.75 vs 6.18 +/- 0.66 h, respectively, indicating that these two kinds of tablets were bioequivalent.",Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17939152/),h,1.3,97334,DB00852,Pseudoephedrine
,17939152,t(1/2),"After a single 0.2 mg dose for the test and reference product, the resulting means of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), C(max), T(max) and t(1/2) of huperzine A were 16.35 +/- 3.42 vs 16.38 +/- 3.61 ng h/mL, 17.53 +/- 3.80 vs 17.70 +/- 3.97 ng h/mL, 2.47 +/- 0.49 vs 2.51 +/- 0.51 ng/mL, 1.3 +/- 0.4 vs 1.2 +/- 0.3 h and 5.92 +/- 0.75 vs 6.18 +/- 0.66 h, respectively, indicating that these two kinds of tablets were bioequivalent.",Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17939152/),h,1.2,97335,DB00852,Pseudoephedrine
,17939152,t(1/2),"After a single 0.2 mg dose for the test and reference product, the resulting means of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), C(max), T(max) and t(1/2) of huperzine A were 16.35 +/- 3.42 vs 16.38 +/- 3.61 ng h/mL, 17.53 +/- 3.80 vs 17.70 +/- 3.97 ng h/mL, 2.47 +/- 0.49 vs 2.51 +/- 0.51 ng/mL, 1.3 +/- 0.4 vs 1.2 +/- 0.3 h and 5.92 +/- 0.75 vs 6.18 +/- 0.66 h, respectively, indicating that these two kinds of tablets were bioequivalent.",Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17939152/),h,5.92,97336,DB00852,Pseudoephedrine
,17939152,t(1/2),"After a single 0.2 mg dose for the test and reference product, the resulting means of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), C(max), T(max) and t(1/2) of huperzine A were 16.35 +/- 3.42 vs 16.38 +/- 3.61 ng h/mL, 17.53 +/- 3.80 vs 17.70 +/- 3.97 ng h/mL, 2.47 +/- 0.49 vs 2.51 +/- 0.51 ng/mL, 1.3 +/- 0.4 vs 1.2 +/- 0.3 h and 5.92 +/- 0.75 vs 6.18 +/- 0.66 h, respectively, indicating that these two kinds of tablets were bioequivalent.",Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17939152/),h,6.18,97337,DB00852,Pseudoephedrine
,16971194,ch,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99830,DB00852,Pseudoephedrine
,16971194,run time,"The method had a chromatographic run time of 12.0 min and a linear calibration curve over the concentration range of 1.0-800 ng/ml for pseudoephedrine and 1.0-400 ng/ml for cetirizine, respectively.",Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: application to phase-I pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971194/),min,12.0,99831,DB00852,Pseudoephedrine
,20356918,oral clearance (Cl/F),"For ibuprofen, oral clearance (Cl/F) was 77.5 + or - 16.4 mL/kg/h and volume of distribution (Vd/F) was 0.147 + or - 0.037 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[ml] / [h·kg],77.5,104154,DB00852,Pseudoephedrine
,20356918,volume of distribution (Vd/F),"For ibuprofen, oral clearance (Cl/F) was 77.5 + or - 16.4 mL/kg/h and volume of distribution (Vd/F) was 0.147 + or - 0.037 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[l] / [kg],0.147,104155,DB00852,Pseudoephedrine
,20356918,Cl/F,"For pseudoephedrine, Cl/F was 12.3 + or - 2.2 mL/kg/min and Vd/F was 2.52 + or - 0.47 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[ml] / [kg·min],12.3,104156,DB00852,Pseudoephedrine
,20356918,Vd/F,"For pseudoephedrine, Cl/F was 12.3 + or - 2.2 mL/kg/min and Vd/F was 2.52 + or - 0.47 L/kg.",Multiple-dose pharmacokinetics and safety of an ibuprofen-pseudoephedrine cold suspension in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20356918/),[l] / [kg],2.52,104157,DB00852,Pseudoephedrine
,19371465,peak concentration,"The peak concentration of ephedrine was 3.88 +/- 1.87 mg/mL (mean +/- SD), which was lower than the WADA permitted value (10 mg/mL).",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),[mg] / [ml],3.88,110077,DB00852,Pseudoephedrine
,19371465,peak concentration,"The peak concentration of ephedrine was 3.88 +/- 1.87 mg/mL (mean +/- SD), which was lower than the WADA permitted value (10 mg/mL).",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),,10,110078,DB00852,Pseudoephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,5.3,110079,DB00852,Pseudoephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,4.9,110080,DB00852,Pseudoephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,4.4,110081,DB00852,Pseudoephedrine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,5.4,110082,DB00852,Pseudoephedrine
,18956778,extraction recovery,"The extraction recovery was 89.1% - 93.5%, 83.9% - 91.3%, and 85.4% - 88.0% accordingly.","[Simultaneous determination of matrine, oxysophocarpin and oxymatrine in rat plasma by HPLC-MS and its application in the pharmacokinetic study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956778/),%,89.1,110824,DB00852,Pseudoephedrine
,18956778,extraction recovery,"The extraction recovery was 89.1% - 93.5%, 83.9% - 91.3%, and 85.4% - 88.0% accordingly.","[Simultaneous determination of matrine, oxysophocarpin and oxymatrine in rat plasma by HPLC-MS and its application in the pharmacokinetic study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956778/),%,93,110825,DB00852,Pseudoephedrine
,18956778,extraction recovery,"The extraction recovery was 89.1% - 93.5%, 83.9% - 91.3%, and 85.4% - 88.0% accordingly.","[Simultaneous determination of matrine, oxysophocarpin and oxymatrine in rat plasma by HPLC-MS and its application in the pharmacokinetic study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956778/),%,83.9,110826,DB00852,Pseudoephedrine
,18956778,extraction recovery,"The extraction recovery was 89.1% - 93.5%, 83.9% - 91.3%, and 85.4% - 88.0% accordingly.","[Simultaneous determination of matrine, oxysophocarpin and oxymatrine in rat plasma by HPLC-MS and its application in the pharmacokinetic study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956778/),%,85.4,110827,DB00852,Pseudoephedrine
,18956778,extraction recovery,"The extraction recovery was 89.1% - 93.5%, 83.9% - 91.3%, and 85.4% - 88.0% accordingly.","[Simultaneous determination of matrine, oxysophocarpin and oxymatrine in rat plasma by HPLC-MS and its application in the pharmacokinetic study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956778/),%,88.0,110828,DB00852,Pseudoephedrine
,15953705,flow rate,Chromatographic separation was performed on an ODS column at flow rate of 0.2 ml/min.,Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[ml] / [min],0.2,111725,DB00852,Pseudoephedrine
,15953705,total chromatographic run time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,10.5,111726,DB00852,Pseudoephedrine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,7.1,111727,DB00852,Pseudoephedrine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,6.2,111728,DB00852,Pseudoephedrine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,2.2,111729,DB00852,Pseudoephedrine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],10,111730,DB00852,Pseudoephedrine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],50,111731,DB00852,Pseudoephedrine
,23339547,plasma half-life (t1/2),"3. The plasma half-life (t1/2) of rasagiline (1.25 mg patch: 11.8 ± 6.5 h, 2.5 mg patch: 12.5 ± 4.7 h) in minipig following transdermal administration was significantly prolonged as compared with that following the oral administration (1 mg tablet: 4.7 ± 2.5 h).",Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23339547/),h,11.8,120131,DB00852,Pseudoephedrine
,23339547,plasma half-life (t1/2),"3. The plasma half-life (t1/2) of rasagiline (1.25 mg patch: 11.8 ± 6.5 h, 2.5 mg patch: 12.5 ± 4.7 h) in minipig following transdermal administration was significantly prolonged as compared with that following the oral administration (1 mg tablet: 4.7 ± 2.5 h).",Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23339547/),h,12.5,120132,DB00852,Pseudoephedrine
,23339547,plasma half-life (t1/2),"3. The plasma half-life (t1/2) of rasagiline (1.25 mg patch: 11.8 ± 6.5 h, 2.5 mg patch: 12.5 ± 4.7 h) in minipig following transdermal administration was significantly prolonged as compared with that following the oral administration (1 mg tablet: 4.7 ± 2.5 h).",Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23339547/),h,4.7,120133,DB00852,Pseudoephedrine
,23339547,dose-normalized relative bioavailability,"The dose-normalized relative bioavailability of rasagiline patch in minipig were 178.5% and 156.4%, respectively, for 1.25 and 2.5 mg patches compared with 1 mg rasagiline tablet.",Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23339547/),%,178.5,120134,DB00852,Pseudoephedrine
,23339547,dose-normalized relative bioavailability,"The dose-normalized relative bioavailability of rasagiline patch in minipig were 178.5% and 156.4%, respectively, for 1.25 and 2.5 mg patches compared with 1 mg rasagiline tablet.",Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23339547/),%,156.4,120135,DB00852,Pseudoephedrine
,14671681,relative bioavailability,"Furthermore, a relative bioavailability of approximately 100% of the preliminary formulation was shown for the newly developed formulation for all parameters.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),%,100,122142,DB00852,Pseudoephedrine
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],1040.66,122143,DB00852,Pseudoephedrine
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],142.28,122144,DB00852,Pseudoephedrine
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],134.52,122145,DB00852,Pseudoephedrine
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],30.34,122146,DB00852,Pseudoephedrine
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.67,122147,DB00852,Pseudoephedrine
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.92,122148,DB00852,Pseudoephedrine
,19926351,flow-rate,"Chromatographic separation was achieved on a C(18) ACE((R)) column (50.0mmx2.1mm, 5mum, Advance Chromatography Technologies, Aberdeen, UK), using an isocratic mobile phase, consisting of water, methanol and formic acid (55:45:0.5, v/v/v), at a flow-rate of 0.3mL/min.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),[ml] / [min],0.3,123111,DB00852,Pseudoephedrine
,19926351,m/,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,279.1,123112,DB00852,Pseudoephedrine
,19926351,m/z,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,165.9,123113,DB00852,Pseudoephedrine
,19926351,m/z,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,172.0,123114,DB00852,Pseudoephedrine
,19926351,m/,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,172.0,123115,DB00852,Pseudoephedrine
,19926351,m/,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,154.0,123116,DB00852,Pseudoephedrine
,19926351,ch,This method had a chromatographic run time of 5.0min and a linear calibration curves ranged from 0.2 to 20.0ng/mL for triprolidine and 5.0-500.0ng/mL for pseudoephedrine.,Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),min,5.0,123117,DB00852,Pseudoephedrine
,19926351,run time,This method had a chromatographic run time of 5.0min and a linear calibration curves ranged from 0.2 to 20.0ng/mL for triprolidine and 5.0-500.0ng/mL for pseudoephedrine.,Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),min,5.0,123118,DB00852,Pseudoephedrine
,19926351,recoveries,"The mean recoveries of triprolidine, pseudoephedrine and gabapentin were 93.6, 76.3 and 82.0% respectively.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),%,93.6,123119,DB00852,Pseudoephedrine
,19926351,recoveries,"The mean recoveries of triprolidine, pseudoephedrine and gabapentin were 93.6, 76.3 and 82.0% respectively.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),%,76.3,123120,DB00852,Pseudoephedrine
,19926351,recoveries,"The mean recoveries of triprolidine, pseudoephedrine and gabapentin were 93.6, 76.3 and 82.0% respectively.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),%,82.0,123121,DB00852,Pseudoephedrine
,16969767,linear dynamic ranges,"The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma.","Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),[ng] / [ml],1-500,123213,DB00852,Pseudoephedrine
,16969767,linear dynamic ranges,"The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma.","Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),[ng] / [ml],2-1000,123214,DB00852,Pseudoephedrine
,16969767,total chromatographic run time,The total chromatographic run time was 2 min and more than 400 human plasma samples could be analyzed in one day by running the system overnight.,"Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969767/),min,2,123215,DB00852,Pseudoephedrine
,11824817,run time,The run time was 4 min.,Rapid determination of pseudoephedrine in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824817/),min,4,130987,DB00852,Pseudoephedrine
,11824817,limit of quant,The limit of quantitation was 5.8 ng/ml using 0.5 ml of plasma.,Rapid determination of pseudoephedrine in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11824817/),[ng] / [ml],5.8,130988,DB00852,Pseudoephedrine
,17230461,total chromatographic run time,The total chromatographic run time of 2 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Quantification of pseudoephedrine in human plasma by LC-MS/MS using mosapride as internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230461/),min,2,139681,DB00852,Pseudoephedrine
,24847268,Cmax,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[μg] / [ml],17.0,146298,DB00852,Pseudoephedrine
,24847268,Cmax,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[μg] / [ml],18.1,146299,DB00852,Pseudoephedrine
,24847268,AUC0-t,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],57.1,146300,DB00852,Pseudoephedrine
,24847268,AUC0-t,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],60.0,146301,DB00852,Pseudoephedrine
,24847268,AUC0-∞,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],59.9,146302,DB00852,Pseudoephedrine
,24847268,AUC0-∞,"For the test formulation, the ibuprofen gMean Cmax was 17.0 μg/mL (vs. 18.1 μg/mL for reference-A), AUC0-t was 57.1 (vs. 60.0 μg·h/mL), and AUC0-∞ was 59.9 μg·h/mL (vs. 63.1 μg·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·μg] / [ml],63.1,146303,DB00852,Pseudoephedrine
,24847268,Cmax,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[ng] / [ml],97.2,146304,DB00852,Pseudoephedrine
,24847268,Cmax,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[ng] / [ml],98.5,146305,DB00852,Pseudoephedrine
,24847268,AUC0-t,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],878.4,146306,DB00852,Pseudoephedrine
,24847268,AUC0-t,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],842.8,146307,DB00852,Pseudoephedrine
,24847268,AUC0-∞,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],907.8,146308,DB00852,Pseudoephedrine
,24847268,AUC0-∞,"For pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL for reference-B), AUC0-t was 878.4 (vs. 842.8 ng·h/mL) and AUC0-∞ was 907.8 ng·h/mL (vs. 868.3 ng·h/mL).","Pharmacokinetics and bioavailability of single dose ibuprofen and pseudoephedrine alone or in combination: a randomized three-period, cross-over trial in healthy Indian volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24847268/),[h·ng] / [ml],868.3,146309,DB00852,Pseudoephedrine
,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,500.43,147763,DB00852,Pseudoephedrine
>,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,167.09,147764,DB00852,Pseudoephedrine
>,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,166.04,147765,DB00852,Pseudoephedrine
>,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,147.88,147766,DB00852,Pseudoephedrine
,17294808,flow rate,"The chromatographic separation was achieved within 3.5 min using the mobile phase consisting of methanol/0.05% formic acid (80:20, v/v) and the flow rate was 1.0 ml/min.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),[ml] / [min],1.0,153366,DB00852,Pseudoephedrine
,17294808,m/z,"Ion signals m/z 181.0 and 148.0 were measured in the positive mode for trimetazidine and pseudoephedrine, respectively.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),,181.0,153367,DB00852,Pseudoephedrine
,17294808,m/z,"Ion signals m/z 181.0 and 148.0 were measured in the positive mode for trimetazidine and pseudoephedrine, respectively.",Quantification of trimetazidine in human plasma by liquid chromatography-electrospray ionization mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294808/),,148.0,153368,DB00852,Pseudoephedrine
,8527687,relative bioavailability,The relative bioavailability of the tablet dosage form with respect to the capsule was found to be 100.8%.,Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527687/),%,100.8,161285,DB00852,Pseudoephedrine
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],666.99,175709,DB00852,Pseudoephedrine
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],650.76,175710,DB00852,Pseudoephedrine
,27514823,Area under the concentration-time curve from 0 to 360 min (AUC0-t ),"Area under the concentration-time curve from 0 to 360 min (AUC0-t ) of EP, PEP and MEP were 666.99, 650.76 and 632.37 µg·min/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[min·μg] / [ml],632.37,175711,DB00852,Pseudoephedrine
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],4.15,175712,DB00852,Pseudoephedrine
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],4.08,175713,DB00852,Pseudoephedrine
,27514823,Maximum plasma concentration (C max),"Maximum plasma concentration (C max) of EP, PEP and MEP were 4.15, 4.08 and 3.59 μg/mL, respectively.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),[μg] / [ml],3.59,175714,DB00852,Pseudoephedrine
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,197.00,175715,DB00852,Pseudoephedrine
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,173.97,175716,DB00852,Pseudoephedrine
,27514823,Mean residence time (MRT),"Mean residence time (MRT) of EP, PEP and MEP were 197.00, 173.97 and 183.87 min, respectively, when the rats were treated with EP-PEP-MEP.","Pharmacokinetic Effects of Cinnamic Acid, Amygdalin, Glycyrrhizic Acid and Liquiritin on Ephedra Alkaloids in Rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27514823/),min,183.87,175717,DB00852,Pseudoephedrine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,15.5,176054,DB00852,Pseudoephedrine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,5.6,176055,DB00852,Pseudoephedrine
,12087345,oral clearance,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),[ml] / [min],0.34,176056,DB00852,Pseudoephedrine
,9435413,serum T concentration,"Acute pharmacokinetic testing showed peak serum hormone levels at 30 min, with a mean serum T concentration of 2688 +/- 147 ng/dL (range, 1820-3770 ng/dL).","Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435413/),[ng] / [dl],2688,195423,DB00852,Pseudoephedrine
,9435413,total T area under the curve,"Levels returned to baseline in 4-6 h, resulting in a total T area under the curve level of 3865 ng/hn.","Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435413/),[ng] / [hn],3865,195424,DB00852,Pseudoephedrine
,25324527,flow rate,"The separation was performed on a Zorbax SB-Aq column (100 mm × 2.1 mm, 3.5 μm) at a flow rate of 0.3 mL/min using acetonitrile-0.1% formic acid aqueous solution as the mobile phase.",Simultaneous quantification and pharmacokinetics of alkaloids in Herba Ephedrae-Radix Aconiti Lateralis extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25324527/),[ml] / [min],0.3,197506,DB00852,Pseudoephedrine
,18799367,flow rate,"Separation of analyte and the internal standard (IS) pseudoephedrine was performed on a Zorbax Extend C(18) column (150 mm x 4.6 mm, 5 microm) with a mobile phase consisting of acetonitrile-5 mM ammonium acetate-acetic acid (40:60:0.05, v/v/v) at a flow rate of 0.5 mL/min.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),[ml] / [min],0.5,205274,DB00852,Pseudoephedrine
,18799367,m/z,"The API 4000 triple quadrupole mass spectrometer was operated in multiple reaction monitoring mode via positive electrospray ionization interface using the transitions m/z 172.1-->m/z (117.1+115.1) for rasagiline, and m/z 166.0-->m/z 148.1 for the internal standard.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),,172.1,205275,DB00852,Pseudoephedrine
,18799367,m/z,"The API 4000 triple quadrupole mass spectrometer was operated in multiple reaction monitoring mode via positive electrospray ionization interface using the transitions m/z 172.1-->m/z (117.1+115.1) for rasagiline, and m/z 166.0-->m/z 148.1 for the internal standard.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),,117.1,205276,DB00852,Pseudoephedrine
,18799367,m/z,"The API 4000 triple quadrupole mass spectrometer was operated in multiple reaction monitoring mode via positive electrospray ionization interface using the transitions m/z 172.1-->m/z (117.1+115.1) for rasagiline, and m/z 166.0-->m/z 148.1 for the internal standard.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),,166.0,205277,DB00852,Pseudoephedrine
,18799367,m/z,"The API 4000 triple quadrupole mass spectrometer was operated in multiple reaction monitoring mode via positive electrospray ionization interface using the transitions m/z 172.1-->m/z (117.1+115.1) for rasagiline, and m/z 166.0-->m/z 148.1 for the internal standard.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),,148.1,205278,DB00852,Pseudoephedrine
,18799367,extraction-efficiency,"The mean extraction-efficiency at three concentrations was 95.6+/-7.0%, 97.9+/-3.0% and 95.3+/-8.3%.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),%,95.6,205279,DB00852,Pseudoephedrine
,18799367,extraction-efficiency,"The mean extraction-efficiency at three concentrations was 95.6+/-7.0%, 97.9+/-3.0% and 95.3+/-8.3%.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),%,97.9,205280,DB00852,Pseudoephedrine
,18799367,extraction-efficiency,"The mean extraction-efficiency at three concentrations was 95.6+/-7.0%, 97.9+/-3.0% and 95.3+/-8.3%.",Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18799367/),%,95.3,205281,DB00852,Pseudoephedrine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,5.2,217311,DB00852,Pseudoephedrine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,8.3,217312,DB00852,Pseudoephedrine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,9.6,217313,DB00852,Pseudoephedrine
,23106955,retention times,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,11.6,217314,DB00852,Pseudoephedrine
less,23106955,total run time,"The retention times of pseudoephedrine, dextrocetirizine, levocetirizine and diazepam (internal standard) were 5.2, 8.3, 9.6 and 11.6 min, respectively, and the total run time was less than 15 min.",Simultaneous determination of levocetirizine and pseudoephedrine in dog plasma by liquid chromatography-mass spectrometry in the presence of dextrocetirizine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23106955/),min,15,217315,DB00852,Pseudoephedrine
,7438686,p,"We presumed that our patient accumulated the drug because of her persistently alkaline urine, which would favor tubular resorption of this weak base (pKa = 9.4).",Renal excretion of pseudoephedrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438686/),,9.4,217535,DB00852,Pseudoephedrine
,7438686,serum elimination half-life,Increasing urine pH increased the serum elimination half-life from 1.9 to 21 hr.,Renal excretion of pseudoephedrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438686/),h,1.9,217536,DB00852,Pseudoephedrine
,7438686,serum elimination half-life,Increasing urine pH increased the serum elimination half-life from 1.9 to 21 hr.,Renal excretion of pseudoephedrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438686/),h,21,217537,DB00852,Pseudoephedrine
,21755810,flow-rate,Pseudoephedrine and I.S. were successfully separated using gradient elution with 0.5% trifluoroacetic acid (TFA) in water and 0.5% TFA in methanol at a flow-rate of 0.2 mL/min.,Reverse-phase liquid chromatography with electrospray ionization/mass spectrometry for the quantification of pseudoephedrine in human plasma and application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755810/),[ml] / [min],0.2,224957,DB00852,Pseudoephedrine
,21755810,m/z,"The ion signals of m/z 166.3 and 180.2 were measured for the protonated molecular ions of pseudoephedrine and I.S., respectively.",Reverse-phase liquid chromatography with electrospray ionization/mass spectrometry for the quantification of pseudoephedrine in human plasma and application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755810/),,166.3,224958,DB00852,Pseudoephedrine
,21755810,m/z,"The ion signals of m/z 166.3 and 180.2 were measured for the protonated molecular ions of pseudoephedrine and I.S., respectively.",Reverse-phase liquid chromatography with electrospray ionization/mass spectrometry for the quantification of pseudoephedrine in human plasma and application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755810/),,180.2,224959,DB00852,Pseudoephedrine
,18972871,flow rate,"The chromatographic separation was performed on a C18 column with a mobile phase of 3 mmol/L ammonium acetate solution-methanol (15:85, v/v) at a flow rate of 0.3 mL/min.",Liquid chromatography-tandem mass spectrometry method for the determination of trimetazidine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18972871/),[ml] / [min],0.3,226638,DB00852,Pseudoephedrine
,16713697,flow-rate,"Chromatographic separation was performed on a Hypurity C18 column (Thermo Hypersil-Keystone 2.1 mm x 150 mm, 5 microm, USA), The mobile phase was composed of 65% methanol and 35% water (contained 0.1% formic acid, 10 mM ammonium formate), which was run with a flow-rate of 0.2 ml/min at 40 degrees C.",Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ml] / [min],0.2,241323,DB00852,Pseudoephedrine
,16713697,limit of detection,The limit of detection for pseudoephedrine and cetirizine each was 5 ng/ml.,Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ng] / [ml],5,241324,DB00852,Pseudoephedrine
higher,28706557,recoveries,The mean recoveries of the three analytes were higher than 75%.,Comparative Pharmacokinetics and Bioavailability of Three Ephedrines in Rat after Oral Administration of Unprocessed and Honey-Fried Ephedra Extract by Response Surface Experimental Design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28706557/),%,75,255765,DB00852,Pseudoephedrine
,493335,plasma clearance,"Average plasma clearance was 67.6 ml/min/kg, with renal clearance averaging 30.3 ml/min/kg.",Pseudoephedrine pharmacokinetics in the rat using a microanalysis technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/493335/),[ml] / [kg·min],67.6,258811,DB00852,Pseudoephedrine
,493335,renal clearance,"Average plasma clearance was 67.6 ml/min/kg, with renal clearance averaging 30.3 ml/min/kg.",Pseudoephedrine pharmacokinetics in the rat using a microanalysis technique. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/493335/),[ml] / [kg·min],30.3,258812,DB00852,Pseudoephedrine
,1880721,Bioavailability,Bioavailability of pseudoephedrine was 91% for fed relative to fasted treatment; for brompheniramine it was 89%.,Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880721/),%,91,259299,DB00852,Pseudoephedrine
,1880721,Bioavailability,Bioavailability of pseudoephedrine was 91% for fed relative to fasted treatment; for brompheniramine it was 89%.,Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880721/),%,89,259300,DB00852,Pseudoephedrine
,19879084,run time,"After sample preparation by liquid-liquid extraction, the analytes and internal standard (diphenhydramine) were analyzed by reversed-phase HPLC on a Venusil Mp-C(18) column (50mmx4.6mm, 5microm) using formic acid:10mM ammonium acetate:methanol (1:40:60, v/v/v) as mobile phase in a run time of 2.6min.","Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879084/),min,2.6,268828,DB00852,Pseudoephedrine
